Inside the mind of the CDMO customer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julien Laizé, Director External Manufacturing CTM at Valneva.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering:

• Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company
• Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification...
• Why the selection process is becoming more and more challenging for buyers
• The importance of reputation and track record for CDMOs, and the value of being known as a specialist
• How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?

Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers, Novo Nordisk and Eli Lilly before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.